An Extensively Humanized Mouse Model to Predict Pathways of Drug Disposition and Drug/Drug Interactions, and to Facilitate Design of Clinical Trials

Colin J. Henderson, Yury Kapelyukh, Nico Scheer, Anja Rode, Aileen McLaren, Kenneth MacLeod, De Lin, J. Wright, L. A. Stanley, C. Roland Wolf (Lead / Corresponding author)

Research output: Contribution to journalArticle

27 Downloads (Pure)

Abstract

Species differences in drug metabolism and disposition can confound the extrapolation of in vivo pharmacokinetic data to man, and also profoundly compromise drug efficacy studies due to differences in pharmacokinetics, in metabolites produced (which are often pharmacologically active) and in differential activation of the transcription factors CAR and PXR which regulate the expression of enzymes such as P450s and drug transporters. These differences have gained additional importance as a consequence of the use of genetically modified mouse models for drug efficacy testing and also patient-derived xenografts to predict individual patient responses to anti-cancer drugs. A number of humanised mouse models for cytochrome P450s, CAR and PXR have been reported. However, the utility of these models has been compromised as a consequence of the redundancy of P450 reactions across gene families where the remaining murine P450s can metabolise the compounds being tested. To remove this confounding factor and create a mouse model which more closely reflects human pathways of drug disposition we have substituted 33 murine P450s from the major gene families involved in drug disposition, together with Car and Pxr, for human CAR, PXR, CYP1A1, CYP1A2, CYP2C9, CYP2D6, CYP3A4 and CYP3A7. We have also created a mouse line where 34 P450s have been deleted from the mouse genome. We demonstrate using model compounds and anti-cancer drugs how these mouse lines can be applied to predict drug-drug interactions in patients and discuss their potential application in the more informed design of clinical trials and the personalised treatment of cancer.
Original languageEnglish
Pages (from-to)601-615
Number of pages15
JournalDrug Metabolism and Disposition
Volume47
Issue number6
Early online date25 Mar 2019
DOIs
Publication statusPublished - Jun 2019

Fingerprint

Drug Interactions
Clinical Trials
Pharmaceutical Preparations
Pharmacokinetics
Cytochrome P-450 CYP3A
Cytochrome P-450 CYP1A2
Neoplasms
Cytochrome P-450 CYP2D6
Cytochrome P-450 CYP1A1
Cytochromes
Heterografts
Genes
Transcription Factors
Genome
Enzymes

Cite this

@article{28fc0e512db94d3e960fa031a9749e77,
title = "An Extensively Humanized Mouse Model to Predict Pathways of Drug Disposition and Drug/Drug Interactions, and to Facilitate Design of Clinical Trials",
abstract = "Species differences in drug metabolism and disposition can confound the extrapolation of in vivo pharmacokinetic data to man, and also profoundly compromise drug efficacy studies due to differences in pharmacokinetics, in metabolites produced (which are often pharmacologically active) and in differential activation of the transcription factors CAR and PXR which regulate the expression of enzymes such as P450s and drug transporters. These differences have gained additional importance as a consequence of the use of genetically modified mouse models for drug efficacy testing and also patient-derived xenografts to predict individual patient responses to anti-cancer drugs. A number of humanised mouse models for cytochrome P450s, CAR and PXR have been reported. However, the utility of these models has been compromised as a consequence of the redundancy of P450 reactions across gene families where the remaining murine P450s can metabolise the compounds being tested. To remove this confounding factor and create a mouse model which more closely reflects human pathways of drug disposition we have substituted 33 murine P450s from the major gene families involved in drug disposition, together with Car and Pxr, for human CAR, PXR, CYP1A1, CYP1A2, CYP2C9, CYP2D6, CYP3A4 and CYP3A7. We have also created a mouse line where 34 P450s have been deleted from the mouse genome. We demonstrate using model compounds and anti-cancer drugs how these mouse lines can be applied to predict drug-drug interactions in patients and discuss their potential application in the more informed design of clinical trials and the personalised treatment of cancer.",
author = "Henderson, {Colin J.} and Yury Kapelyukh and Nico Scheer and Anja Rode and Aileen McLaren and Kenneth MacLeod and De Lin and J. Wright and Stanley, {L. A.} and Wolf, {C. Roland}",
note = "This research was supported by a Cancer Research UK Programme Grant [C4639/A10822] and Medical Research Council Project Grant MR/R017506/1.",
year = "2019",
month = "6",
doi = "10.1124/dmd.119.086397",
language = "English",
volume = "47",
pages = "601--615",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "6",

}

An Extensively Humanized Mouse Model to Predict Pathways of Drug Disposition and Drug/Drug Interactions, and to Facilitate Design of Clinical Trials. / Henderson, Colin J.; Kapelyukh, Yury; Scheer, Nico; Rode, Anja; McLaren, Aileen; MacLeod, Kenneth; Lin, De; Wright, J.; Stanley, L. A.; Wolf, C. Roland (Lead / Corresponding author).

In: Drug Metabolism and Disposition, Vol. 47, No. 6, 06.2019, p. 601-615.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An Extensively Humanized Mouse Model to Predict Pathways of Drug Disposition and Drug/Drug Interactions, and to Facilitate Design of Clinical Trials

AU - Henderson, Colin J.

AU - Kapelyukh, Yury

AU - Scheer, Nico

AU - Rode, Anja

AU - McLaren, Aileen

AU - MacLeod, Kenneth

AU - Lin, De

AU - Wright, J.

AU - Stanley, L. A.

AU - Wolf, C. Roland

N1 - This research was supported by a Cancer Research UK Programme Grant [C4639/A10822] and Medical Research Council Project Grant MR/R017506/1.

PY - 2019/6

Y1 - 2019/6

N2 - Species differences in drug metabolism and disposition can confound the extrapolation of in vivo pharmacokinetic data to man, and also profoundly compromise drug efficacy studies due to differences in pharmacokinetics, in metabolites produced (which are often pharmacologically active) and in differential activation of the transcription factors CAR and PXR which regulate the expression of enzymes such as P450s and drug transporters. These differences have gained additional importance as a consequence of the use of genetically modified mouse models for drug efficacy testing and also patient-derived xenografts to predict individual patient responses to anti-cancer drugs. A number of humanised mouse models for cytochrome P450s, CAR and PXR have been reported. However, the utility of these models has been compromised as a consequence of the redundancy of P450 reactions across gene families where the remaining murine P450s can metabolise the compounds being tested. To remove this confounding factor and create a mouse model which more closely reflects human pathways of drug disposition we have substituted 33 murine P450s from the major gene families involved in drug disposition, together with Car and Pxr, for human CAR, PXR, CYP1A1, CYP1A2, CYP2C9, CYP2D6, CYP3A4 and CYP3A7. We have also created a mouse line where 34 P450s have been deleted from the mouse genome. We demonstrate using model compounds and anti-cancer drugs how these mouse lines can be applied to predict drug-drug interactions in patients and discuss their potential application in the more informed design of clinical trials and the personalised treatment of cancer.

AB - Species differences in drug metabolism and disposition can confound the extrapolation of in vivo pharmacokinetic data to man, and also profoundly compromise drug efficacy studies due to differences in pharmacokinetics, in metabolites produced (which are often pharmacologically active) and in differential activation of the transcription factors CAR and PXR which regulate the expression of enzymes such as P450s and drug transporters. These differences have gained additional importance as a consequence of the use of genetically modified mouse models for drug efficacy testing and also patient-derived xenografts to predict individual patient responses to anti-cancer drugs. A number of humanised mouse models for cytochrome P450s, CAR and PXR have been reported. However, the utility of these models has been compromised as a consequence of the redundancy of P450 reactions across gene families where the remaining murine P450s can metabolise the compounds being tested. To remove this confounding factor and create a mouse model which more closely reflects human pathways of drug disposition we have substituted 33 murine P450s from the major gene families involved in drug disposition, together with Car and Pxr, for human CAR, PXR, CYP1A1, CYP1A2, CYP2C9, CYP2D6, CYP3A4 and CYP3A7. We have also created a mouse line where 34 P450s have been deleted from the mouse genome. We demonstrate using model compounds and anti-cancer drugs how these mouse lines can be applied to predict drug-drug interactions in patients and discuss their potential application in the more informed design of clinical trials and the personalised treatment of cancer.

UR - http://www.scopus.com/inward/record.url?scp=85058591394&partnerID=8YFLogxK

U2 - 10.1124/dmd.119.086397

DO - 10.1124/dmd.119.086397

M3 - Article

VL - 47

SP - 601

EP - 615

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 6

ER -